TUSC2 and lung carcinoma: [57] provided evidence that myristoylation-deficient mutants cell lines of Fus1 (also known as TUSC2 tumour suppressor candidate 2, a tumour suppressor associated with lung cancer) lose tumour suppressor activity, and thus myristoylation may play a role in delaying lung carcinogenesis; however, it is unclear whether NMT1 or NMT2 is the catalyst in this process.